Vanda Pharmaceuticals (NASDAQ: VNDA) just announced that it has received FDA-approval for its new drug known as BYSANTI. The drug is meant to treat Bipolar I manic episodes as well as Schizophrenia ...

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment ...

The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

Vanda Pharmaceuticals had 9% revenue growth and heavy losses with a 1.4x sales valuation and a PDUFA date. Check out why VNDA stock is downgraded to hold.

By Sneha S K and Kunal Das Feb 20 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' drug for the treatment of two serious mental health conditions, the company said ...

Vanda Pharmaceuticals (NASDAQ: VNDA) has secured FDA approval for its new drug, BYSANTI (milsaperidone), marking a significant milestone for the biotech company. The treatment is approved for Bipolar ...

B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a valuation that is a "historic discount" and is "untenable." The firm has a ...

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder Provided by PR Newswire Jan 8, 2026, 4:00:00 AM Vanda Pharmaceuticals ...

Multiyear agreement includes exclusive Monumental Sports Network studio entitlement, activations across Capitals, Wizards, and Mystics, and deep integration via community and media platforms For ...

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI ...